Pharmidex attending SMR Meeting 'New Developments in Transnational Technologies'
March 17, 2016

SMR meeting focusing on Translational technologies on the 17th of March 2016

Pharmidex will be attending the SMR meeting entitled New Developments in Translational Technologies.

This years meeting focus is very much inline with Pharmidex areas of operation and interest. We look forward to seeing you there on the 17th of March 2016


Modern drug discovery undergoes continual change in our efforts to more effectively design new life changing therapeutics for patients. One area that has seen a massive increase in focus in recent years has been the need for more translational approaches to many if not all therapeutic areas.


This has stemmed from the increasing appreciation that many of the cellular and animal models, traditionally used for the assessment of efficacy, currently have limited predictive validity to the human diseases we are trying to treat. Additionally, target selection based solely on preclinical validation may be leading to flawed biological hypothesise for putative therapeutics. Together these factors have contributed to the poor clinical success rate in many diseases. As a result there has been an increased focus on identify targets based on a strong understanding of human genetics and disease biology. Additionally drug discovery teams are increasingly co- developing translational approaches to demonstrate target engagement and proof of pharmacology whilst identifying biomarkers to stratify patient populations in which to optimally test proof of concept.



This meeting brings together experts from a variety of imaging and preclinical model backgrounds across a range of diseases (dementia, pain and oncology) to present and discuss their experiences in the various aspects of translational science. This promises to be an exciting and interesting meeting with in depth discussion into how the drug discovery community can better target disease processes, more optimally test novel therapeutics in appropriate populations and ultimately enhance clinical success in producing efficacious therapeutics for patients.


Please see the link for further details: http://www.smr.org.uk/SMR/Meetings/20160317/Default.asp

February 9, 2026
We’re excited to announce that Pharmidex has expanded its analytical capabilities with the addition of the xMAP INTELLIFLEX™ system, a powerful, high-performance platform for multiplex biomarker analysis. This advanced technology enables the simultaneous measurement of multiple analytes from minimal sample volumes, delivering exceptional sensitivity, accuracy and reproducibility. It is ideally suited for complex biological matrices and supports a wide range of applications, from biomarker discovery to translational and preclinical studies.  Our INTELLIFLEX™ supports dual reporter channels to collect more data per sample. 🔬 What this means for our partners and the wider scientific community: • Faster, data-rich insights from fewer samples • Enhanced assay flexibility and scalability • Improved data quality to support confident decision-making • Greater efficiency across drug discovery and development programmes This investment strengthens Pharmidex’s commitment to scientific excellence, allowing us to deliver even more robust, innovative and reliable services to pharma, biotech, CROs and academic collaborators. We look forward to putting this new capability to work in support of better science and better medicines.
February 4, 2026
At Pharmidex , we deliver high-quality LC-MS bioanalysis to support drug development across a wide range of analysis. Our experienced team supports preclinical, translational and clinical studies, providing accurate, reliable data under GLP and GCP to help drive confident decision-making. Learn more about our LC-MS capabilities: https://www.pharmidex.com/Discovery-Bioanalysis
February 2, 2026
Pharmidex offers high-quality Clinical Chemistry services delivering accurate, reliable data to support drug development. Our expert team and robust, quality-driven workflows enable trusted results that help accelerate decision-making and strengthen collaboration with pharma companies, CROs and academic partners. By working together, we support better science and more efficient drug development. 👉 Learn more: https://www.pharmidex.com/Clinical-chemistry
More Posts